Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT ID: NCT00911651

Last Updated: 2009-06-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-06-30
• Study Completion Date: 2008-08-31

Brief Summary

The objectives of this study are to assess the effect of salbutamol in comparison with ipratropium bromide on the geometry of central and peripheral airways and to correlate spirometric indices with the Computational Fluid Dynamics (CFD) based calculated airway volumes and resistances for both compounds.

Detailed Description

Salbutamol (VentolinTM) is a short acting beta agonist (SABA) which is used to treat wheezing, dyspnea and breathing difficulties caused by asthma and COPD. Further, it is also used to prevent bronchospasm during exercise.

Ipratropium bromide (Atrovent® HFA) is a short acting anticholinergic bronchodilator (short acting muscarinic antagonist (SAMA)) that improves lung function, dyspnea, exercise tolerance and health-related quality of life in patients with COPD. Studies have also shown that ipratropium bromide might reduce COPD exacerbations and related hospitalisations because the extended bronchodilatation might reduce infection rates by improving clearance of respiratory secretions.

In this open, randomized, two-way crossover, pilot study the effect of salbutamol in patients with moderate and severe COPD will be examined in comparison with the effects of ipratropium bromide. These patients will receive 400 µg salbutamol and 80 µg ipratropium bromide in a randomized crossover design.

The objectives of this study are to assess the effect of salbutamol in comparison with ipratropium bromide on the geometry of central and peripheral airways and to correlate spirometric indices (as Forced Expiratory Volume in one second (FEV1) and Tiffeneau index) with the Computational Fluid Dynamics (CFD) based calculated airway volumes and resistances for both compounds.

Conditions

COPD

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

salbutamol

6 patients with moderate (GOLD 2) and severe (GOLD 3) COPD

Group Type: ACTIVE_COMPARATOR

Salbutamol

Intervention Type: DRUG

400 µg inhalation once

ipratropium bromide

COPD patients GOLD stage II and III

Group Type: ACTIVE_COMPARATOR

ipratropium bromide

Intervention Type: DRUG

80 µg inhalation once

Interventions

Salbutamol

400 µg inhalation once

Intervention Type: DRUG

ipratropium bromide

80 µg inhalation once

Intervention Type: DRUG

Other Intervention Names

Ventolin; atrovent

Eligibility Criteria

Inclusion Criteria

1. Patients with documented COPD based on the following criteria:

• Smoking history of at least 10 pack-years.
• Decreased Tiffeneau index (FEV1/(F)VC < 0.70).

2. Patients aged ≥ 40 years.

3. Patients should present moderate to severe COPD with an FEV1 between 30 and 80% of predicted (GOLD 2 and 3).

4. Patients should be treated according to GOLD guidelines.

5. Able to inhale study drug.

6. Maintained on stable respiratory medications for 6 weeks prior to visit 1.

7. Able to perform lung function tests.

8. Able to follow study procedures.

Exclusion Criteria

1. Patients who are allergic to salbutamol, ipratropium bromide or to another element of the product.

2. Patients allergic to sojalecithin and products on the basis of soja and peanut.

3. Patients who have or ever had glaucoma.

4. Patients with urinary problems, prostate hyperplasy or bladder-neck obstruction. Patients whose symptoms are controlled on treatment may be included.

5. Patients with a recent history (i.e. six months or less) of myocardial infarction.

6. Patients with any unstable or life threatening cardiac arrhythmia.

7. Patients with severe kidney insufficiency (creatinine clearance ≤50 ml/min)a.

8. Patients below the age of 40.

9. Patients who are pregnant or are breast-feeding.

10. Patients who are treated with other anticholinergic medications, that cannot be stopped during the study period.

11. A respiratory infection or exacerbation of COPD in the four weeks prior to screening.

12. Significant alcohol or drug abuse within the past 12 months.

13. Participation in another trial with an investigational drug within one month or six half lives (whichever is greater) prior to screening visit.

14. Known active tuberculosis.

15. A history of asthma, cystic fibrosis, central bronchiectasis, interstitial lung disease or pulmonary thromboembolic disease.

16. A history of thoracotomy with pulmonary resection.

17. Active or untreated malignancy.

18. Use of oral corticosteroid medication at unstable doses (i.e. less than six weeks on a stable dose) or at doses ≥ 10 mg/day.

a Cockroft's formulae should be applied: in male: creatinine clearance = (140-age) x weight / 72 x creatininemia in female: creatinine clearance = 0.85 x (140-age) x weight / 72 x creatininemia

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: collaborator

University Hospital, Antwerp

OTHER

Sponsor Role: lead

Responsible Party

Antwerp University Hospital

Principal Investigators

Wilfried A De Backer, MD PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Antwerp

Locations

Antwerp University Hospital

Antwerp, Antwerp, Belgium

Countries

Belgium

Other Identifiers

PML_DOC_0801

Identifier Type: -

Identifier Source: org_study_id